03 Profile
Vital Signsby Bridgehead
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Respiratory (asthma/COPD)
Photo: Bluesky
Academic
Dr Chloe Bloom
Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK
Sept 2026Oct 2026Nov 2026to date
1
Quoted in the press, across 1 topic since 7 Sept 2026
02 Quoted on · 1 of 29 topics
Dr Chloe Bloom: key facts
- Kind of voice
- Academic
- Role
- Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK
- Quoted on
- Respiratory (asthma/COPD)
- Press coverage
- Quoted in the press
- Most recently quoted
- 15 Oct 2026
- First quoted
- 7 Sept 2026
04 The signal · where Dr Chloe Bloom sits on respiratory (asthma/copd)
Leading
One of the voices most often quoted in the press on respiratory (asthma/copd).
Placed by press coverage on this topic only, not across all topics.
Dr Andy WhittamoreClinicianClinical Lead (and practising GP), Asthma + Lung UKLeading- Dr Amina Al-YassinClinicianClinical Lead for Children and Young People's Services at Brent Integrated Care PartnershipLeading
- Are HolmAcademicHead of the Department of Respiratory Medicine at Oslo University Hospital RikshospitaletLeading
- Claire AdamsClinicianRespiratory clinical lead at North East and North Cumbria Integrated Care BoardLeading
- Matt SwallowClinicianDr, clinical lead at Asthma + Lung UKLeading
- Dr Chloe BloomAcademicClinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UKLeading
Dr Samantha WalkerSector leaderDirector of Research and Innovation, Asthma + Lung UKLeading- Karen SpillettSector leaderdeputy head of health advice at Asthma + Lung UKLeading
Showing the leading voices and those placed around Dr Chloe Bloom · See every voice on the topic →
05 On the record · press
What Dr Chloe Bloom has said
By outlet · bar length shows relative volume
- cambridge-news.co.uk
- everydayhealth.com
- femalefirst.co.uk
- hospitalpharmacyeurope.com
- independent.co.uk
Where Dr Chloe Bloom has been quoted
- Semaglutide significantly reduces asthma attacks and COPD exacerbations, study findshospitalpharmacyeurope.com · 15 Oct 2026
- Semaglutide linked to 40% reduction in asthma attacksthepharmacist.co.uk · 23 Sept 2026
- Fat jabs could slash risk of killer asthma attacks up to 40%, study suggeststhesun.co.uk · 9 Sept 2026
- GLP-1s May Reduce Asthma Attack Frequency, Study Suggestseverydayhealth.com · 8 Sept 2026
- Weight-loss jabs could cut asthma attacksfemalefirst.co.uk · 8 Sept 2026
- Asthma patients taking weight-loss medication see 'attacks reduction'cambridge-news.co.uk · 8 Sept 2026
- People with asthma who take semaglutide have fewer attacks, study showsindependent.co.uk · 7 Sept 2026
- Ozempic and Wegovy linked to nearly 40% fewer asthma attackssciencedaily.com
How we found the articles that name Dr Chloe Bloom: we searched news for these terms.
- asthma
- COPD
- respiratory disease
- lung cancer screening
- pulmonary
Also searched with “asthma” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Respiratory (asthma/COPD)
Verbatim
“People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance”
“GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.”
“The findings from this study are encouraging, but they should not change treatment decisions on their own.”
“Obesity is strongly associated with asthma. People with asthma who also have obesity and/or type 2 diabetes tend to have more symptoms and a higher risk of asthma attacks.”
“The findings from this study are encouraging, but they should not change treatment decisions on their own.”
“The findings from this study are encouraging, but they should not change treatment decisions on their own. People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance.”
“GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes, however, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials”
“GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Asthma Salbutamol blue inhaler reminder as pharmacist issues messageWales Online
- UK pharmacist Salbutamol reminder for anyone taking blue inhaler for asthmaThe Mirror
- Fallowfield Grandad shares shock at being diagnosed with lung cancer despite having no symptoms – now he’s helping scientists look for cancer clues hidden in bloodAbout Manchester
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.